Neurotech International Ltd (ASX:NTI) Signs Development Agreement for Cannabinoid Therapies
Partnership Agreement
Neurotech International Ltd (ASX:NTI) has entered into a development agreement with RH Farma Dooel Skopje (RH Pharma), a subsidiary of European Cannabis Company (ECC). The partnership aims to develop a broad-spectrum cannabinoid drug product for pediatric neurodevelopmental disorders using RH Pharma’s proprietary CO extraction technology.
Development Plans
Under the agreement, RH Pharma will utilize GMP-compliant processes to produce Neurotech’s cannabinoid formulations, ensuring high-quality and scalable production. The initial term includes an upfront payment of €25,000 and additional services as requested by Neurotech over 12 months.
Executive Comments
Dr Anthony Filippis, CEO and Managing Director of Neurotech International, stated, “As we accelerate our plans for registration of NTI64 in Australia via a provisional registration strategy initially, it will be important for Neurotech to scale production to meet future product demand upon regulatory approval(s). Our commitment to regulatory compliance and quality is further strengthened by collaborations with leading medical institutions and key clinicians, reinforcing our position within the industry. We are delighted to partner with ECC, a company renowned for its expertise in cannabis product development. This agreement not only accelerates our global growth strategy but also ensures we can deliver premium-quality products with unparalleled consistency and scalability, independent of strain-specific limitations.”
Motley Fool contributor Abbie Stokes has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.